Lung Cancer (NSCLC): A Study Of Lorlatinib Versus Crizotinib In First Line Treatment
Of Patients With ALK-Positive NSCLC
What are the effects of the study drugs, lorlatinib when given alone to crizotinib
given alone and which is better for treating ALK-positive NSCLC?
Basic Study Information
Purpose:Location: Cancer Center
If you participate in this research study, you will be assigned by chance (like flip
of a coin or drawing straws) to receive either lorlatinib alone (Group A) or crizotinib
alone (Group B). You will have a 50% (1 in 2) chance of receiving lorlatinib, and
a 50% (1 in 2) chance of receiving crizotinib. Neither you nor your doctor can choose
the group you will be in.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03052608?term=B7461006&rank=1
Study Reference #: ILUN17067
Lead Researcher (Principal Investigator)
Lead Researcher: Megan Baumgart
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Learn More About These Conditions
More information about Lung Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search